Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 434 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Vascular Disorders Clear all

Conditions: Retinal Vein Occlusion, Diabetic Macular Edema, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion
Interventions: Aflibercept; Drug
Lead sponsor: Justis Ehlers; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Age-related Macular Degeneration, Diabetic Retinopathy, Glaucoma
Interventions: Visual acuity (presenting and pinhole), Optical coherence tomography (OCT), Intraocular pressure, Active linkage to care, Fundus Photography; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 60 Years and older
Enrollment: 60,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Retinal Vein Occlusion, Macular Edema
Interventions: dexamethasone intravitreal implant 0.7 mg; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Von Hippel-Lindau Disease, CNS Hemangioblastoma, Retinal Hemangioblastoma
Interventions: PTK787/ZK 222584; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 2
States / cities: Boston, Massachusetts • Durham, North Carolina

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: 700 µg Dexamethasone, 350 µg Dexamethasone, Sham Injection; Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetic Nephropathy, Diabetic Retinopathy
Interventions: CIIIT; Drug
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 1995
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma, AMD, Diabetic Retinopathy (DR)
Interventions: Chronic Disease Intervention CDI; Other
Lead sponsor: Interstat LLC; Other
Eligibility: 18 Years to 99 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Diabetic Retinopathy
Interventions: Ophthalmic Telemedicine; Procedure
Lead sponsor: Legacy Health System; Other
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Wichita, Kansas • Pendleton, Oregon

Conditions: Branch Retinal Vein Occlusion
Interventions: Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 26
States / cities: Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more

Conditions: Diabetes Mellitus
Interventions: Diabetes Mobile Application; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 14 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetic Macular Edema
Interventions: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321), Macular Laser Photocoagulation; Drug · Procedure
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 51
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 48 more

Conditions: Retinal Disease, Corneal Disease, Diabetic Retinopathy, Uveitis, Age-Related Macular Degeneration
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 3,833 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration, AMD, Macular Degeneration, Age-related, 10, Eye Diseases, Retinal Degeneration, Retinal Diseases
Interventions: X-82, Anti-VEGF, Placebo; Drug
Lead sponsor: Tyrogenex; Industry
Eligibility: 50 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 35
States / cities: Tucson, Arizona • Beverly Hills, California • Huntington Beach, California + 32 more

Conditions: Retinal Detachment, Vitrectomy, Proliferative Vitreoretinopathy, Diabetic Retinopathy
Interventions: 1000 centistoke silicone oil, 5000 centistoke silicone oil; Procedure
Lead sponsor: Mid Atlantic Retina; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Macular Degeneration
Interventions: Angiography, Laser Treatment; Procedure
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Age-related Macular Degeneration, Diabetic Retinopathy, Hypertensive Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion
Interventions: Phase variance optical coherence tomography (PV-OCT); Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: VEGF Trap-Eye 2.0mg, Sham; Biological · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more

Conditions: Retinal Vein Occlusion
Interventions: ANXV; Biological
Lead sponsor: Annexin Pharmaceuticals AB; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: West Monroe, Louisiana • Hagerstown, Maryland • Tulsa, Oklahoma + 4 more

Conditions: Diabetic Retinopathy, Neurotrophic Keratitis
Interventions: Not listed
Lead sponsor: Medical Center Ophthalmology Associates; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Timeline: 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Intraocular Inflammation, Suspected Endophthalmitis
Interventions: Non Applicable; Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 155,413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Diabetes, Diabetic Retinopathy
Interventions: No intervention; Device
Lead sponsor: iHealthScreen Inc; Industry
Eligibility: 22 Years and older
Enrollment: 935 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Richmond Hill, New York

Conditions: Retinal Vasculitis
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Branch Retinal Vein Occlusion
Interventions: pegaptanib sodium (Macugen); Drug
Lead sponsor: Palmetto Retina Center, LLC; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Los Angeles, California • Hagerstown, Maryland • West Columbia, South Carolina

Conditions: Diabetic Retinopathy
Interventions: AKST4290, Placebo; Drug
Lead sponsor: Alkahest, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 17
States / cities: Phoenix, Arizona • Glendale, California • Huntington Beach, California + 13 more

Search by objective public record fields.

Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO

Village-Integrated Eye Worker Trial II

Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

Anti-Nephropathic Effects of Chronic Intermittent Intravenous Insulin Therapy (CIIIT)

A Real-World Study of Interventional Clinical Outcomes in Patients With Open Angle Glaucoma and Other Chronic Eye Diseases

The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

Mobile Application to Enhance Diabetic Care

Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema

Tissue Studies of Human Eye Diseases

X-82 to Treat Age-related Macular Degeneration

Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments

Identification and Treatment of Feeder Vessels in Macular Degeneration

Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion

An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity

A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022

Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy

Optical Coherence Tomography (OCT) in Retinal Vasculitis

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)